Press Release

August 06, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Press Release - Q1 FY27 Results Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose a Press Release, inter alia covering the Unaudited Financial Results of the Company for the quarter ended June 30, 2026. The above is for your information and dissemination. Thanking you, For LUPIN LIMITED AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754) Encl.: a/a LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com Press Release BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN Lupin Q1 FY2027 Results Mumbai, August 06, 2026: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending June 30, 2026. These unaudited results were taken on record by the Board of Directors at a meeting held today. Financial Highlights – Consolidated IND-AS Amt in INR Mn Quarter Particulars Q1 FY2027 Q1 FY2026 YoY Growth % Q4 FY2026 QoQ Growth % Sales 82,172 61,638 ↑ 33.3% 73,919 ↑ 11.2% EBITDA* 25,799 18,063 ↑ 42.8% 26,263 ↓ 1.8% EBITDA Margin (%)* 31.4% 29.3% ↑ 210 bps 35.5% ↓ 410 bps PBT 20,174 14,155 ↑ 42.5% 19,280 ↑ 4.6% PAT 14,170 12,215 ↑ 16.0% 14,687 ↓ 3.5% *Includes forex & other income Income Statement Highlights – Q1 FY2027  Gross Profit was up 39.5% at INR 61,280 Mn from INR 43,919 Mn in Q1 FY2026, with a gross margin of 74.6%.  Personnel cost was 16.8% of sales at INR 13,830 Mn compared to INR 10,830 Mn in Q1 FY2026.  Manufacturing and other expenses were 28.5% of sales at INR 23,412 Mn compared to INR 17,720 Mn in Q1 FY2026.  PBT at INR 20,174 Mn was 24.6% of sales, up 42.5% YoY from INR 14,155 Mn in Q1 FY2026.  Investment in R&D for the quarter was INR 6,077 Mn (7.4% of sales). Balance Sheet highlights  Operating working capital was INR 82,596 Mn as on June 30, 2026. Operating days for quarter stood at 90 days.  Capital Expenditure for the quarter was INR 2,786 Mn.  Net Debt as on June 30, 2026, stands at INR -28,308 Mn.  Net Debt Equity as on June 30, 2026, stands at -0.12. Mr. Nilesh Gupta, Managing Director, Lupin Limited said “We are pleased to begin FY27 with a strong performance, driven by robust growth across our key markets and continued improvement in profitability. Our focus on execution, operational excellence, and sustained investments in technology and innovation continue to strengthen the business and position us for sustainable, profitable growth over the long term”. Page 1 of 5 Press Release BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN Consolidated Financial Results Q1 FY2027 Amt in INR Mn Q1 % of Q1 % of YoY Q4 % of QoQ Particulars FY2027 sales FY2026 sales Growth % FY2026 sales Growth % Sales 82,172 100.0% 61,638 100.0% ↑ 33.3% 73,919 100.0% ↑ 11.2% Other operating income 597 0.7% 1,045 1.7% ↓ 42.9% 828 1.1% ↓ 27.9% Total Revenue from 82,769 100.7% 62,683 101.7% ↑ 32.0% 74,747 101.1% ↑ 10.7% operations Material cost 20,892 25.4% 17,719 28.7% ↑ 17.9% 18,516 25.0% ↑ 12.8% Gross Profit (excluding 61,280 74.6% 43,919 71.3% ↑ 39.5% 55,403 75.0% ↑ 10.6% Other operating income) Employee cost 13,830 16.8% 10,830 17.6% ↑ 27.7% 12,427 16.8% ↑ 11.3% Manufacturing & Other 23,412 28.5% 17,720 28.7% ↑ 32.1% 22,093 29.9% ↑ 6.0% expenses Other Income 1,303 1.6% 790 1.3% ↑ 64.9% 1,407 1.9% ↓ 7.4% Forex Loss / (Gain) 139 0.2% (859) -1.4% ↓ 116.2% (3,145) -4.3% ↓ 104.4% EBITDA 25,799 31.4% 18,063 29.3% ↑ 42.8% 26,263 35.5% ↓ 1.8% Depreciation, Amortization 4,529 5.5% 2,990 4.9% ↑ 51.5% 4,468 6.0% ↑ 1.4% & Impairment expense EBIT 21,270 25.9% 15,073 24.5% ↑ 41.1% 21,795 29.5% ↓ 2.4% Finance cost 1,096 1.3% 918 1.5% ↑ 19.4% 1,202 1.6% ↓ 8.8% Profit Before Tax (PBT) and 20,174 24.6% 14,155 23.0% ↑ 42.5% 20,593 27.9% ↓ 2.0% Exceptional items Exceptional item (Net) - - - - - 1,313 1.8% ↓100.0% Profit Before Tax (PBT) 20,174 24.6% 14,155 23.0% ↑ 42.5% 19,280 26.1% ↑ 4.6% Tax 6,004 7.3% 1,940 3.1% ↑ 209.5% 4,593 6.2% ↑ 30.7% Profit After Tax (PAT) 14,170 17.2% 12,215 19.8% ↑ 16.0% 14,687 19.9% ↓ 3.5% (-) Share of Loss from JV 0 0.0% - - - - - - (-) Non-Controlling Interest 20 0.0% 24 0.0% ↓ 16.7% 83 0.1% ↓ 75.9% Profit/(Loss) for the period 14,150 17.2% 12,191 19.8% ↑ 16.1% 14,604 19.8% ↓ 3.1% Page 2 of 5 Press Release BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN Sales Mix Amt in INR Mn Particulars Q1 FY2027 Q1 FY2026 YOY Growth % Q4 FY2026 QoQ Growth % U.S. 34,348 24,041 ↑ 42.9% 33,987 ↑ 1.1% India 23,796 20,894 ↑ 13.9% 19,082 ↑ 24.7% Other Developed Markets 11,494 7,748 ↑ 48.3% 8,453 ↑ 36.0% Emerging Markets 9,897 6,524 ↑ 51.7% 9,906 ↓ 0.1% Total Formulations 79,535 59,207 ↑ 34.3% 71,428 ↑ 11.3% API 2,637 2,431 ↑ 8.5% 2,491 ↑ 5.9% Total Product Sales 82,172 61,638 ↑ 33.3% 73,919 ↑ 11.2% Q1 FY2027 Sales Mix Page 3 of 5 Press Release BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN Operational Highlights U.S. U.S. sales for Q1 FY2027 were INR 34,348 Mn up 42.9% compared to INR 24,041 Mn in Q1 FY2026; (USD 366 Mn in Q1 FY2027 compared with USD 282 Mn in Q1 FY2026); accounting for 42% of Lupin’s global sales. The Company received 6 ANDA approvals from the U.S. FDA, and launched 3 products in the quarter in the U.S. The Company now has 149 generic products in the U.S Market. Lupin continues to be the 3rd largest pharmaceutical player in both U.S. generic market and U.S. total market by prescriptions (IQVIA Quarter June 2026). Lupin is the leader in 56 of its marketed generics in the U.S. and amongst the Top 3 in 112 of its marketed products (IQVIA Quarter June 2026 by extended units). India India sales for Q1 FY2027 were INR 23,796 Mn, up 13.9% compared to INR 20,894 Mn in Q1 FY2026; accounting for 29% of Lupin’s global sales. India Region Formulation sales up by 15.1% in the quarter as compared to Q1 FY2026. The Company launched 7 brands across therapies during the quarter. Lupin is the 8th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2026). Other Developed Markets Other Developed markets sales for Q1 FY2027 were INR 11,494 Mn, up 48.3% compared to INR 7,748 Mn in Q1 FY2026; accounting for 14% of Lupin’s global sales. Emerging Markets Emerging Markets sales for Q1 FY2027 were INR 9,897 Mn, up 51.7% compared to INR 6,524 Mn in Q1 FY2026; accounting for 12% of Lupin’s global sales. Global API Global API sales for Q1 FY2027 were INR 2,637 Mn, up 8.5% compared to INR 2,431 Mn in Q1 FY2026; accounting for 3% of Lupin’s global sales. Research and Development Investment in R&D was INR 6,077 Mn (7.4% of sales) for the quarter as compared to INR 4,975 Mn (8.1% of sales) for Q1 FY2026. Lupin received approval for 6 ANDAs from the U.S. FDA in the quarter. Cumulative ANDA filings with the U.S. FDA stand at 429 as of June 30, 2026, with the company having received 350 approvals to date. The Company now has 50 First-to-File (FTF) filings including 21 exclusive FTF opportunities. Cumulative U.S. DMF filings stand at 94 as of June 30, 2026. Page 4 of 5 Press Release BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas [Showing first 8,000 characters — download PDF for full document]